Drugs / bevasiranib
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00722384 | Aug 2004 → Aug 2007 | macular degeneration | OPKO Health, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00306904 | Jan 2006 → Sep 2007 | diabetic macular edema | OPKO Health, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00259753 | Jul 2005 → Dec 2007 | macular degeneration | OPKO Health, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00557791 | Nov 2009 → Jul 2011 | age-related macular degeneration | OPKO Health, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00499590 | Aug 2007 → Mar 2009 | macular degeneration | OPKO Health, Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bevasiranib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00557791 ↗ |
| Known as | BEVASIRANIB SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110581 ↗ |
| Known as | CAND5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110581 ↗ |
| Action | Activate | “Toll-like receptor 3 activator” CHEMBL2110581 ↗ |
| Action | Inhibit | “selectively silences the mRNA encoding for VEGF” NCT00259753 ↗ |
| Route | Intravitreal | “for Intravitreal Injection” NCT00259753 ↗ |
| Target | TLR3 | “Toll-like receptor 3 activator” CHEMBL2110581 ↗ |